BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma

Oncogene

Volumn 25, Issue 33, 2006, Pages 4525-4533

  Goldsmith, K C ^a   Liu, X ^a   Dam, V ^a   Morgan, B T ^a   Shabbout, M ^a   Cnaan, A ^a,b   Letai, A ^c   Korsmeyer, S J ^c   Hogarty, M D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2 homologues; MYCN; Neuroblastoma; Programmed cell death

Indexed keywords

ARGININE; ASPARAGINYLLEUCYLTRYPTOPHYLALANYLALANYLGLUTAMINYLARGINYLTYROSYLGLYCYLARGINY LGLUTAMYLLEUCYLARGINYLARGINYLMETHIONYLSERYLASPARTYLGLUTAMYLPHENYLALANYLVALYLASPA RTYLSERYLPHENYLALANYLLYSYLLYSINE; BH3 PROTEIN; CASPASE 9; GLUTAMYLASPARTYLISOLEUCYLISOLEUCYLARGINYLASPARAGINYLISOLEUCYLALANYLARGINYLH ISTIDYLALANYLALANYLGLUTAMINYLVALYLGLYCYLALANYLSERYLMETHIONYLASPARTYLARGININE; GLUTAMYLASPARTYLISOLEUCYLISOLEUCYLARGINYLASPARAGINYLISOLEUCYLALANYLARGINYLH ISTIDYLLEUCYLALANYLGLUTAMINYLVALYLGLYCYLASPARTYLSERYLMETHIONYLASPARTYLARGININE; PEPTIDE; PEPTIDE DERIVATIVE; PEPTIDE FRAGMENT; PEPTIDOMIMETIC AGENT; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; MITOCHONDRION; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TREATMENT FAILURE; TUMOR GROWTH; XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PEPTIDE FRAGMENTS; PEPTIDES; PROTO-ONCOGENE PROTEINS; TIME FACTORS;

EID: 33746843081     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209489     Document Type: Article

References (39)

1. Biedler JL, Spengler BA. (1976). J Natl Cancer Inst 57: 683-695.
2. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Mol Cell 17: 393-403.
3. Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK. (2004). Stem Cells 22: 1111-1120.
4. Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR. (1997). Curr Biol 7: 913-920.
5. Dive C, Evans CA, Whetton AD. (1992). Semin Cancer Biol 3: 417-427.
6. Feder MK, Gilbert F. (1983). J Natl Cancer Inst 70: 1051-1056.
7. Green DR, Reed JC. (1998). Science 281: 1309-1312.
8. Hersey P, Zhang XD. (2003). J Cell Physiol 196: 9-18.
9. Holinger EP, Chittenden T, Lutz RJ. (1999). J Biol Chem 274: 13298-13304.
10. Jacks T, Weinberg RA. (2002). Cell 111: 923-925.
11. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ et al. (2001). Cancer Res 61: 6185-6193.
12. Korsmeyer SJ. (1992). Cancer Surv 15: 105-118.
13. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. (2005). Mol Cell 17: 525-535.
14. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Cancer Cell 2: 183-192.
15. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. (2004). Cancer Cell 6: 241-249.
16. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. (1999). New Engl J Med 341: 1165-1173.
17. Moreau C, Cartron PF, Hunt A, Meflah K, Green DR, Evan G et al. (2003). J Biol Chem 278: 19426-19435.
18. Nicholson DW. (2000). Nature 407: 810-816.
19. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. (2003). Cell 112: 29-40.
20. Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM. (1996). Proc Natl Acad Sci USA 93: 15190-15194.
21. Reed JC. (1995). Curr Opin Oncol 7: 541-546.
22. Reed JC. (1999). J Clin Oncol 17: 2941-2953.
23. Reed JC. (2003). Cancer Cell 3: 17-22.
24. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP. (1986). J Natl Cancer Inst 76: 375-387.
25. Schlesinger HR, Gerson JM, Moorhead PS, Maguire H, Hummeler K. (1976). Cancer Res 36: 3094-3100.
26. Schmechel D, Marangos PJ, Brightman M. (1978). Nature 276: 834-836.
27. Schmitt CA, McCurrach ME, de_Stanchina E, Wallace_ Brodeur RR, Lowe SW. (1999). Gene Dev 13: 2670-2677.
28. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F et al. (1983). Nature 305: 245-248.
29. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001). Nature 409: 207-211.
30. Sutherland RM. (1988). Science 240: 177-184.
31. Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H et al. (2003). Clin Cancer Res 9: 3345-3355.
32. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Nat Med 6: 529-535.
33. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. (1970). Cancer Res 30: 2110-2118.
34. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. (2001). Cancer Res 61: 8-13.
35. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V et al. (2004). Cancer Cell 6: 625-630.
36. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. (2003). Science 302: 1036-1038.
37. Wadia JS, Dowdy SF. (2002). Curr Opin Biotechnol 13: 52-56.
38. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. (2004). Science 305: 1466-1470.
39. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. (2001). Science 292: 727-730.